Market Overview

Benzinga's Top Downgrades

Related TEVA
Teva Announces UK High Court Gives Positive Judgment In The Company's Patent Case Against AstraZeneca
Notable Hedge Funds Disclose Additions And Reductions To Holdings
Sofinnova Ventures Closes $500M Fund (Fox Business)
Related RVBD
Elliot Management Says Cash Offer Of $21/Share For Riverbed Still Stands
Riverbed Misses 2Q Views; Offers Outlook Above Consensus

Analysts at Canaccord downgraded Teva Pharmaceutical Industries (NYSE: TEVA) from “buy” to “hold.” The target price for Teva has been raised from $50 to $45. Teva's shares closed at $37.96 yesterday.

Analysts at FBR Capital downgraded Riverbed Technology (NASDAQ: RVBD) from “outperform” to “market perform.” The target price for Riverbed has been lowered from $28 to $20. Riverbed's shares closed at $20.10 yesterday.

Analysts at Roth Capital downgraded Skullcandy (NASDAQ: SKUL) from “buy” to “neutral.” The target price for Skullcandy is set to $7. Skullcandy's shares closed at $6.61 yesterday.

CRT Capital downgraded Alpha Natural Resources (NYSE: ANR) from “buy” to “fair value.” The target price for Alpha Natural is set to $8. Alpha Natural's shares closed at $8.51 yesterday.

Latest Ratings for TEVA

DateFirmActionFromTo
Aug 2014UBSMaintainsNeutral
Jul 2014JP MorganMaintainsNeutral
Jul 2014BarclaysMaintainsOverweight

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (RVBD + ANR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters